Senate confirmation of Heidi Overton as FDA commissioner hinges on the Nov. 18 Senate HELP Committee vote and any subsequent floor action before Democrats assume Senate control in January. Nominated in August after Marty Makary’s May departure, Overton faces bipartisan resistance tied to her White House role advancing vaccine schedule changes and MAHA priorities, alongside questions on mifepristone access and regulatory speed. Key Republican senators including Chair Bill Cassidy remain uncommitted, and Democrats are expected to oppose, meaning any single GOP defection could block advancement in committee. Recent developments include her September hearing testimony pledging to follow the law on contested issues, the post-midterm lame-duck timeline pressure, and White House contingency planning for alternatives such as acting leadership. These factors shape trader assessments of confirmation probability ahead of the committee threshold.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว1H6H1D7D30DALL
View resolved

ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย